-+ 0.00%
-+ 0.00%
-+ 0.00%

We Think You Should Be Aware Of Some Concerning Factors In Medicamen Biotech's (NSE:MEDICAMEQ) Earnings

Simply Wall St·11/21/2026 03:08:50
Listen to the news

Following the solid earnings report from Medicamen Biotech Limited (NSE:MEDICAMEQ), the market responded by bidding up the stock price. While the profit numbers were good, our analysis has found some concerning factors that shareholders should be aware of.

earnings-and-revenue-history
NSEI:MEDICAMEQ Earnings and Revenue History November 21st 2026

To understand the value of a company's earnings growth, it is imperative to consider any dilution of shareholders' interests. As it happens, Medicamen Biotech issued 6.7% more new shares over the last year. Therefore, each share now receives a smaller portion of profit. To talk about net income, without noticing earnings per share, is to be distracted by the big numbers while ignoring the smaller numbers that talk to per share value. You can see a chart of Medicamen Biotech's EPS by clicking here.

How Is Dilution Impacting Medicamen Biotech's Earnings Per Share (EPS)?

Medicamen Biotech's net profit dropped by 18% per year over the last three years. On the bright side, in the last twelve months it grew profit by 20%. On the other hand, earnings per share are only up 21% over the same period. So you can see that the dilution has had a bit of an impact on shareholders.

Changes in the share price do tend to reflect changes in earnings per share, in the long run. So Medicamen Biotech shareholders will want to see that EPS figure continue to increase. But on the other hand, we'd be far less excited to learn profit (but not EPS) was improving. For that reason, you could say that EPS is more important that net income in the long run, assuming the goal is to assess whether a company's share price might grow.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Medicamen Biotech.

Our Take On Medicamen Biotech's Profit Performance

Each Medicamen Biotech share now gets a meaningfully smaller slice of its overall profit, due to dilution of existing shareholders. Therefore, it seems possible to us that Medicamen Biotech's true underlying earnings power is actually less than its statutory profit. But at least holders can take some solace from the 21% EPS growth in the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For instance, we've identified 3 warning signs for Medicamen Biotech (1 is significant) you should be familiar with.

This note has only looked at a single factor that sheds light on the nature of Medicamen Biotech's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.